Заключение

На сегодняшний день, ВNP и NT-про-ВNP являются предпочтительными маркерами для сердечной недостаточности. Способность определять незрелые и активные молекулярные формы натрийуретических пептидов у пациентов с сердечной недостаточностью может быть клинически важным для построения терапии. Поэтому изучение этих пептидов остается важной задачей для исследователей.

Список литературы

1. Hall C. Essential biochemistry and physiology of (NT-pro)BNP./ Eur. J. Heart Fail. - 2004. - P. 257-260.

2. Liang F., ORear J., Schellenberger U., Tai L., Lasecki M., Schreiner GF., Apple FS., Maisel AS., Pollitt NS., Protter AA.. Evidence for functional heterogeneity of circulating B-type natriureticpeptide./ J Am Coll Cardiol. - 2007;№49. P.: 875-1071

3. Liao X., Wang W., Chen S., Wu Q.. Role of glycosilation in corin zymogen activation./ J. Biol. Chem. - 2007; № 282 (38),P.: 28-35.

4. Ma K., Banas K., de Bold J. Determinants of inducible brain natriyretic peptide promoter activity./ Reg. Peptides. - 2005 Jan;P.:169-170.

5. Sudoh T., Maekawa K., Kojima M., Minamino N., Kangawa K., Matsuo H.. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide./ Biochem. Biophys. Res. Commun. - 1989; №159. P.: 27-34.

6. Ationu A, Carter ND. Molecular forms of brain and atrial natriuretic peptides in transplanted human heart./ Br J Biomed Sci. - 1994; №51 (4) P.: 207-316

7. Casco VH., Veinot JP., Kuroski de Bold ML., Masters RG., Stevenson MM., de Bold AJ. Natriuretic peptide system gene expression in human coronary arteries./ J. Histochem. Cytochem. - 2002; №50.P.: 799-809.

8. Colucci WS., Elkayam U., Horton DP., Abraham WT., Bourge RC., Johnson AD., Wagoner LE., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure./ N. Engl. J. // Med. - 2000; №27.P.: 246-253.

9. Cowie MR., Mendez GF.. BNP and congestive heart failure. /Prog. Cardiovasc. Dis. - 2002; №44. P.: 293-320.

10. De Lemos JA., McGuire DK., Drazner MH.. B-type natriuretic peptide in cardiovascular disease./ Lancet - 2003; №362.P.: 274-316

11. Goetze JP.. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. /Clin Chem. - 2004; №50.P.: 1503-1510.

12. Hammerer-Lercher A., Neubauer E., Mьller S., Pachinger O., Puschendorf B., Mair J.. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction./ Clin. Chim. Acta - 2001; №310.P.: 193-197.

13. He Q., Wang D., Yang X., Carretero OA., LaPointe MC.. Inducible regulation of human brain natriuretic peptide promoter in transgenic mice. /Am J Physiol Heart Circ Physiol. - 2001; №280.P.: 368-376.

14. Hosoda K., Nakao K., Mukoyama M., Saito Y., Jougasaki M., Shirakami G., et al. Expression of brain natriuretic peptide gene in human heart. /Hypertension - 1991;№17.P.: 1152-1156.

15. Huang W., Lee M., Perng H., Yang S., Kuo S., Chang H.. Circulating brain natriuretic peptide values in healthy men before and after exercise. /Metabolism. - 2002; 51. P.: 1423-1425.

16. Hughes D., Talwar S., Squire I. B., Davies J. E., Ng L. L.. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction./ Clin. Sci. - 1999; 96.P.: 373-380.

17. Kambayashi Y., Nakao K., Mukoyama M., Saito Y., Ogawa Y., Shiono S., et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium. /FEBS. Lett. - 1990; 259. P.: 341-345.

18. Kita T., Kida O., Yokota N., Eto T., Minamino N., Kangawa K., et al. Effect of brain natriuretic peptide-45, a circulating form of brain natriuretic peptide, in spontaneously hypertensive rats. /Eur. J. Pharmacol. - 1991; 202. P.: 73-79.

19. Kohno M., Yokokawa K., Yasunari K. et al. Changes in plasma cardiac natriuretic peptide concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy// Int. J. Clin. Pharmacol. Ther. - 1997; 35. P.: 38-42

20. Levin ER., Gardner DG., Samson WK.. Natriuretic peptides. /N. Engl. J. Med. - 1998; 339. P.: 321-328.

21. Maack, T. The broad homeostatic role of natriuretic peptides./ Arq Bras Endocrinol Metabol 50, - 2006. P.:198-207.

22. Mair J., Hammerer-Lercher A., Puschendorf B.. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. /Clin. Chem. Lab. Med. - 2001;39.P.: 571-88.

23. Matsukawa N., Grzesik WJ., Takahashi N., Pandey KN., Pang S., Yamauchi M., Smithies O.. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. /Proc. Natl. Acad. Sci.// USA - 1999; 96.P.: 7403-7408.

24. Mukoyama M., Nakao K., Hosoda K., Suga S., Saito Y., Ogawa Y., et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. /J. Clin. Invest. - 1991; 87.P.: 1402-1412.

25. Nakao K., Ogawa Y., Suga S., Imura H.. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. /J. Hypertens. - 1992; №10.P.: 4-11

26. Nakao K., Ogawa Y., Suga S., Imura H.. Molecular biology and biochemistry of the natriuretic peptide system. /I: Natriuretic peptides. J. Hypertens. - 1992; №10.P.: 907-912.

27. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. /Eur. J. Heart. Fail. - 2004; №6.P.: 289-293.

28. Potter LR., Hunter T.. Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. /J. Biol. Chem. - 2001; 276.P.: 57-60.

29. Rockwell NC., Krysan DJ., Komiyama T., Fuller RS.. Precursor processing by Kex2/Furin proteases. /Chem Rev. - 2002; 102.P.: 4525-4548.

30. Rose, R.A., and Giles, W.R. Natriuretic peptide C receptor signalling in the heart and vasculature. /J Physiol 586, - 2008.P.: 353-366.

31. Seino Y., Ogawa A., Yamashita T., Fukushima M., Ogata K., Fukumoto H., Takano T.. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. /Eur. J. Heart Fail. - 2004; №6.P.: 295-300.

32. Shimizu H., Masuta K., Aono K., Asada H., Sasakura K., et al. Molecular forms of human brain natriuretic peptide in plasma. /Clin. Chim. Acta. - 2002; 316.P.: 129-135.

33. Sudoh T., Kangawa K., Minamino N. et al. A new natriuretic peptide in porcine brain // Nature 1988; 332.P.: 78-81.

34. Tateyama H, Hino J, Minamino N, Kangawa K, Ogihara T, Matsuo H. Characterization of immunoreactive brain natriuretic peptide in human cardiac atrium. /Biochem Biophys Res Commun. - 1990; 14;166(3): 1080-7.

35. Togashi K., Hirata Y., Ando K., Takei Y., Kawakami M., Marumo F.. Brain natriuretic peptide-like immunoreactivity is present in human plasma. /FEBS. Lett. - 1989; 250:235-7.

36. Tsuruda T., Boerrigter G. Huntley BK., Noser JA., Cataliotti A., Costello-Boerrigter LC., et al. Brain natriuretic peptide is prodused in cardiac fibroblasts and induces matrix metalloproteinases. /Circ. Res. - 2002; P.:91: 27-31.

37. Vaderheyden M., Bartunek J., Goethals M.. Brain and other natriuretic peptides: molecular aspects. /Eur. J. Heart Fail. - 2004; 6.P.: 261-268.

38. Valli N., Gobinet A., Bordenave L.. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. /J. Lab. Clin. Med. - 1999; №134.P.: 437-444.

39. Wu F., Yan W., Pan J., Morser J., Wu Q.. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes./ J. Biol. Chem. - 2002; 277.P.: 900-905

40. Xu-Cai, Y.O., and Wu, Q. (2009). Molecular forms of natriuretic peptides in heart failure and their implications. /Heart 96, P.:419-424.

41. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. /Circulation - 1994; 90. P.: 195-203.